Johns Hopkins University is enrolling FL-HCC patients to assess the safety and tolerability of targeted therapy (DNAJB1-PRKACA fusion kinase) in combination with nivolumab and ipilimumab (NCT04248569). This evidence concerns the gene PRKACA and hepatocellular carcinoma.